Distribution of nuchal translucency in antenatal screening for Down s syndrome. JPBestwick,WJHuttlyandNJWald... METHODS
|
|
- Samson Nelson
- 7 years ago
- Views:
Transcription
1 8 ORIGINAL ARTICLE Distribution of nuchal translucency in antenatal screening for JPBestwick,WJHuttlyandNJWald... J Med Screen 2010;17:8 12 DOI: /jms See end of article for authors affiliations... Correspondence to: J P Bestwick, Wolfson Institute of Preventive Medicine, Barts and the London Queen Marys School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK; j.p.bestwick@qmul.ac.uk Accepted for publication 17 January Objective To determine whether the standard deviation of nuchal translucency (NT) measurements has decreased over time and if so to revise the estimate and assess the effect of revising the estimate of the standard deviation on the performance of antenatal screening for. Setting Data from a routine antenatal screening programme for comprising 106 affected and 22,640 unaffected. Methods NT measurements were converted into multiple of the median (MoM) values and standard deviations of log 10 MoM values were calculated in affected and unaffected. The screening performance of the Combined and s (that include NT measurement) were compared using previous and revised estimates of the standard deviation. Results The standard deviation of NT in unaffected has reduced over time (from 1998 to 2008) (e.g. from to [log 10 MoM] at completed weeks of pregnancy, reducing the variance by about 30%). This was not observed in affected. Compared with results from the serum, urine and ultrasound screening study (SURUSS), use of the revised NT standard deviations in unaffected resulted in an approximate 20% decrease in the false-positive rate for a given detection rate; for example, from 2.1% to 1.7% (a 19% reduction) at a 90% detection rate using the with first trimester markers measured at 11 completed weeks gestation and from 4.4% to 3.5% (a 20% reduction) at an 85% detection rate using the at 11 completed weeks. Conclusions The standard deviation of NT has declined over time and using the revised estimates improves the screening performance of tests that incorporate an NT measurement. INTRODUCTION Nuchal translucency (NT) is useful as an antenatal screening marker for in the late first trimester of pregnancy. It forms part of the (NT and serum markers pregnancyassociated plasma protein-a [PAPP-A] and free b-human chorionic gonadotrophin [free b-hcg] measured between 10 and 13 weeks gestation) and part of the (NT and PAPP-A measured between 10 and 13 weeks and serum markers alphafetoprotein, unconjugated oestriol, free b-hcg and inhibin-a measured between 14 and 22 weeks gestation). In monitoring our screening programme at the Wolfson Institute of Preventive Medicine, London, there was an indication that the standard deviation of NT in unaffected decreased over time. This prompted us to investigate the observation further to obtain a revised estimate of the standard deviation. We then investigated the impact of the revised standard deviation on screening performance compared with results from the Serum, Urine and Ultrasound Screening Study (SURUSS). 1 METHODS We used data from 22,719 women who attended two London antenatal clinics (at University College Hospital and the Whittington Hospital) between January 2003 and December 2008 for antenatal screening for using the Combined or s. The tests were performed at the Wolfson Institute of Preventive Medicine. We also included data from 27 women who were not offered these screening tests because of high NT measurements and whose were subsequently diagnosed as being affected with (median NT 4.9 mm). were recorded from the two hospitals, the regional cytogenetic unit and the National Down Syndrome Cytogenetic Register. NT values were converted into multiple of the median (MoM) values by dividing measured NT values by the expected NT for a given crown rump length (CRL) (obtained from a log linear regression of median log NT measurements against median CRL measurements in 5 mm categories of CRL [weighted by the number of women in each category]). Table 1 gives details of the used in our analyses.
2 Distribution of NT in antenatal screening for 9 Table 1 Maternal and gestational age, and NT in Down s syndrome and unaffected Median age (years) Median CRL (mm) Gestational age 10 weeks gestation weeks gestation weeks gestation 50 10, weeks gestation Total ,640 Median NT (mm) Median NT (MoM) 10 weeks gestation weeks gestation weeks gestation weeks gestation CRL, crown rump length; NT, nuchal translucency, MoM, multiple of the median Standard deviations of NT MoM values (based on all data) and the median NT MoM values according to gestational age were calculated in and unaffected. Gestational age was estimated from CRL using the equation reported by Robinson and Fleming. 2 Screening performance was expressed as detection rates for specified false-positive rates, false-positive rates for specified detection rates and detection and false-positive rates for specified risk cut-offs. For the Combined and Integrated tests, screening performance was estimated for the population of maternities in England and Wales , 3 for comparison with published estimates from SURUSS. 1 Detection and false-positive rates were estimated by numerical integration of the multivariate Gaussian distributions of MoM values in and unaffected, using the maternal age distribution and distribution parameters (means, standard deviations and correlation coefficients) for serum markers previously published 1,4,5 except for the standard deviation of NT in unaffected, which was found to be significantly lower than estimates made in studies conducted in the past and the truncation limits for NT (see the Results). The median NT MoM values and standard deviations in were similar to those previously reported, so it was not necessary to revise these (see the Results). Screening performance estimates apply to the detection of in the early second trimester. Too few data are available on affected at 10 weeks, so screening performance was estimated for 11, 12 and 13 completed weeks of gestation only. RESULTS Table 2 shows the expected median MoM values (regressed) and standard deviations of the (log 10 ) MoM value in Down s syndrome and unaffected in this study compared with those reported in SURUSS. 1 The standard deviations in unaffected were lower than those reported in SURUSS (the standard deviations at 12 and 13 weeks were similar [ and , respectively], and therefore combined). In, the median MoM values and standard deviation were similar to those reported in SURUSS. Figure 1 shows the relative frequency distributions of NT in and unaffected using previous estimates of the standard deviation in unaffected and revised estimates at 11, 12 and 13 completed weeks gestation. As a single screening test considered without maternal age, NT alone has revised detection rates of 71%, 68% and 61% for a 5% false-positive rate at 11, 12 and 13 completed weeks, respectively, compared with previous estimates of 67%, 63% and 55%, respectively. 1 Truncation limits for NT (also given in Table 2) were Table 2 Median, standard deviation and truncation limits of NT MoM values in and unaffected : estimates from the present study and estimates from SURUSS 1,4,5 Estimates from present study Estimates from SURUSS Median NT MoM (regressed) 10 completed weeks completed weeks completed weeks completed weeks Standard deviation (log 10 MoM) 10 completed weeks ) } completed weeks 12 completed weeks 0: completed weeks Trunction limits (MoM) 10 completed weeks ) 11 completed weeks completed weeks :65 2:50 13 completed weeks NT, nuchal translucency; SURUSS, Serum, Urine and Ultrasound Screening Study; MoM, multiple of the median P ¼ P, Journal of Medical Screening 2010 Volume 17 Number 1
3 10 Bestwick et al. Figure 1 Relative frequency distributions of nuchal translucency (NT) multiple of the median (MoM) values in and unaffected according to gestational age. Solid line is previous distribution and dashed line is revised distribution. Median MoM in at vertical line Figure 2 Probability plots of nuchal translucency in unaffected according to week of gestation Table 3 Screening performance estimates of NT, and according to completed week of first trimester measurements: estimates with revised standard deviations and truncation limits and estimates using SURUSS parameters Estimates using revised unaffected standard deviations and revised truncation limits Estimates using SURUSS parameters 1,4,5 Screening test (include maternal age) DR (%) for FPR of FPR (%) for DR of DR (%) for FPR of FPR (%) for DR of 1% 3% 5% 75% 80% 85% 90% 1% 3% 5% 75% 80% 85% 90% 11 completed weeks completed weeks completed weeks completed weeks completed weeks completed weeks SURUSS, Serum, Urine and Ultrasound Screening Study; NT, nuchal translucency; DR, detection rate; FPR, false-positive rate
4 Distribution of NT in antenatal screening for 11 Table 4 Screening performance estimates of the and according to completed week of first trimester measurements and early second trimester risk cut-off: estimates with revised standard deviations and truncation limits and estimates using SURUSS parameters Risk cut-off Screening test (include maternal age) 1 in 50 1 in in in in in 300 DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR Estimates using revised unaffected standard deviations and revised truncation limits 11 completed weeks : : : : : :23 12 completed weeks : : : : : :24 13 completed weeks : : : : : :28 11 completed weeks : : : : : :13 12 completed weeks : : : : : :14 13 completed weeks : : : : : :17 Estimates using SURUSS parameters 1,4,5 11 completed weeks : : : : : :25 12 completed weeks : : : : : :28 13 completed weeks : : : : : :33 11 completed weeks : : : : : :14 12 completed weeks : : : : : :17 13 completed weeks : : : : : :20 DR, detection rate; FPR, false-positive rate; OAPR, odds of being affected given a positive test result; SURUSS, Serum, Urine and Ultrasound Screening Study Journal of Medical Screening 2010 Volume 17 Number 1
5 12 Bestwick et al. revised based on probability plots of NT MoM values (see Figure 2) and to prevent the reversal of risk at lower NT MoM values 4 (i.e. risk of decreasing with smaller NT measurements and then increasing with further decreases in NT). Table 3 shows the effect of the revised distribution parameters based on the decreased NT standard deviation in unaffected and the revised truncation limits compared with those from SURUSS on the screening performance of the at 11, 12 and 13 completed weeks gestation and the with first-stage measurements at 11, 12 and 13 completed weeks gestation. The revised false-positive rates for a given detection rate are about 20% lower than previous estimates. For example, at an 85% detection rate the false-positive rate using the at 11 completed weeks gestation is 3.5% instead of 4.4% (or about 9 fewer false-positives per 1000 women screened), and at a 90% detection rate using the with first-stage measurements at 11 completed weeks gestation, the false-positive rate is 1.7% instead of 2.1% (4 fewer false-positives per 1000 women screened). The relative reduction in the false-positive rate is greater at lower detection rates; for example, at an 80% detection rate the false-positive rate is reduced by 25% (from 2.4% to 1.8%) with the at 11 completed weeks. Table 4 shows screening performance of the Combined and s using the revised and the previous estimates according to risk cut-off. DISCUSSION The standard deviation of NT in unaffected has decreased over time. At weeks gestation, our revised standard deviation of log 10 NT MoM (0.1105) represents a 17% decrease in the standard deviation or a 31% decrease in the variance compared with the standard deviation reported in 2003 in SURUSS (0.1329). 1 Data from the Fetal Medicine Foundation show a similar trend; an estimate of the standard deviation in unaffected in 1998 was 0.120, 6 compared with in 2008 (from Figure 4 of Wright et al. 7 ), a similar decrease in the standard deviation of 19% or decrease in the variance of 35%. The explanation for this decrease is uncertain; it could be a result of greater magnification of the fetal image with improvements in instrumentation together with sonographers having become more experienced in the measurement of NT. A declining trend in the standard deviation in was not observed, perhaps because NT tends to be large in such, so precise measurements would have been possible anyway. There were too few data to examine whether the standard deviation decreased with gestation as it did in unaffected. Exclusion of data from women in whom clinical action was taken on grounds of a high NT alone results in a smaller standard deviation (0.17 compared with 0.24 for all women), but to provide accurate risks of having an affected pregnancy it is necessary to use the standard deviation based on all women. When a screening marker has different standard deviations in affected and unaffected risk reversal will occur, and if they are markedly different it will occur within nonextreme values of the marker. 4 Accordingly, it is reasonable to set truncation limits near the point of risk reversal. Previously, a single lower truncation limit was suggested (0.65 MoM), but with the smaller standard deviation in unaffected, it is necessary to have week-specific lower truncation limits to avoid the phenomenon of risk reversal. The previously reported upper truncation limit of 2.5 MoM from 10 to 13 weeks is still applicable. The improvement in screening performance shown in Table 3 that arises from the smaller standard deviations of NT in unaffected, while small is clinically useful an approximate reduction in the false-positive rate of 20% or about four fewer false-positive per 1000 women screened without a reduction in the detection rate. The improvement in estimated screening performance was similar for the Combined and s.... Authors affiliations J P Bestwick, Academic Fellow in Medical Statistics, Wolfson Institute of Preventive Medicine, Barts and the London Queen Marys School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK W J Huttly, Antentatal Screening Manager, Wolfson Institute of Preventive Medicine, Barts and the London Queen Marys School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK N J Wald, Professor, Wolfson Institute of Preventive Medicine, Barts and the London Queen Marys School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK Declaration of interests Nicholas Wald holds a patent for the. He is a Director of Logical Medical Systems Ltd, which produces software for the interpretation of Down syndrome screening tests. ACKNOWLEDGEMENTS We thank Patricia Jones (University College Hospital), Angela Dietrich and Ilke Nezvat (Whittington Hospital) for their assistance in the ascertainment of the cases of. REFERENCES 1 Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for : the results of the serum, urine and ultrasound screening study (SURUSS). J Med Screen 2003;10: Robinson HP, Fleming JEE. A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975:82; Office for National Statistics. Birth Statistics. England and Wales; 1996; 1997; 1998 (FMI, Nos ). London: The Stationary Office, Morris JK, Wald NJ. Graphical presentation of distributions of risk in screening. J Med Screen 2005;12: Wald N, Rodeck C, Rudnicka A, Hackshaw A. Nuchal translucency and gestational age. Prenat Diagn 2004;24: Nicolaides KH, Snijders RJM, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998;18: Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376 83
Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers
DOI: 10.1002/pd.4019 ORIGINAL ARTICLE Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers Kevin Spencer* and Nicholas J. Cowans
More informationMaternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester
PRENATAL DIAGNOSIS Prenat Diagn 2000; 20: 390±394. Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester Kevin Spencer 1 *, Natasha Tul 2 and Kypros H. Nicolaides 2
More informationScreening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at 11 + 0to13+ 6 weeks
Ultrasound Obstet Gynecol 2006; 27: 151 155 Published online 30 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.2699 Screening for trisomy 21 by fetal tricuspid regurgitation,
More informationThe National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report
0 The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report Joan K Morris, Elizabeth De Souza December 2009 National Down Syndrome Cytogenetic Register Queen Mary University
More informationCorrespondence: Dr K. Spencer, Endocrine Unit, Clinical Biochemistry Department, Harold Wood Hospital, Gubbins Lane, Romford, Essex, RM3 0BE, UK
Ultrasound Obstet Gynecol 1999;:231 237 A screening program for trisomy 21 at 10 14 using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-a
More informationRisk Calculation Software Requirements for Down's Syndrome Screening
Screening Programmes Fetal Anomaly Risk Calculation Software Requirements for Down's Syndrome Screening Version 1 January 2013 Created by: Dave Wright, Barry Nix, Steve Turner, David Worthington and Andy
More informationjournal of medicine The new england First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome abstract
The new england journal of medicine established in 1812 november 10, 2005 vol. 353 no. 19 First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome Fergal D. Malone, M.D., Jacob A. Canick,
More informationcfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation.
Reports of Major Impact www.ajog.org Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population Kypros H. Nicolaides, MD; Argyro Syngelaki, RM; Ghalia Ashoor, MD;
More informationClinical Studies Abstract Booklet
Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January
More informationSonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation
American Journal of Obstetrics and Gynecology (2006) 194, 397 401 www.ajog.org Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation Aris T. Papageorghiou, MD, a Kyriaki Avgidou, MD, a
More informationScreening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow
Ultrasound Obstet Gynecol 1998;12:380 384 Screening for chromosomal abnormalities at 10 14 weeks: the role of ductus venosus blood flow A. Matias*, C. Gomes*, N. Flack*, N. Montenegro and K. H. Nicolaides*
More informationThe 11 13 +6 weeks scan
The 11 13 +6 weeks scan Kypros H. Nicolaides The 11 13 +6 weeks scan Fetal Medicine Foundation, London 2004 Dedication to Herodotos & Despina Contents Introduction 1. First trimester diagnosis of chromosomal
More informationFrontomaxillary and mandibulomaxillary facial angles at 11 + 0to13+ 6 weeks in fetuses with trisomy 18
Ultrasound Obstet Gynecol 2007; 30: 928 933 Published online 1 November 2007 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.2/uog.5188 Frontomaxillary and mandibulomaxillary facial angles
More informationPrenatal Screening for Fetal Aneuploidy in Singleton Pregnancies
No. 261 (Replaces No. 187, February 2007) Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies This clinical practice guideline has been prepared by the Genetics Committee of the Society of
More informationImplementation of maternal blood cell-free DNA testing in early screening for aneuploidies
Ultrasound Obstet Gynecol 2013; 42: 34 40 Published online 7 June 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12504 Implementation of maternal blood cell-free DNA testing in
More informationEffect of incorrect gestational dating on Down s syndrome and neural tube risk assessment
Original Article Ann Clin Biochem 2001; 38: 230±234 Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment S N Millner From the Department of Pathology, University of
More informationFirst- and Second-Trimester Evaluation of Risk for Down Syndrome
Original Research First- and Second-Trimester Evaluation of Risk for Down Syndrome Robert H. Ball, MD, Aaron B. Caughey, MD, MPP, Fergal D. Malone, MD, David A. Nyberg, MD, Christine H. Comstock, MD, George
More informationPrenatal screening and diagnostic tests
Prenatal screening and diagnostic tests Contents Introduction 3 First trimester routine tests in the mother 3 Testing for health conditions in the baby 4 Why would you have a prenatal test? 6 What are
More informationThe California Prenatal Screening Program
The California Prenatal Screening Program Provider ook netic Disease Screening Program Quad Marker Screening Serum Integrated Screening Full Integrated Screening TABLE OF CONTENTS WELCOME to the California
More informationDepartment of Obstetrics and Gynecology, Kayseri Military Hospital, Kayseri, Turkey
Orıgınal Article Obstetrics & Gynecology North Clin Istanbul 2015;2(2):92-100 doi: 10.14744/nci.2015.08370 A prospective study to assess the clinical impact of interobserver reliability of sonographic
More informationFetal size and dating: charts recommended for clinical obstetric practice
Fetal size and dating: charts recommended for clinical obstetric practice Pam Loughna 1, Lyn Chitty 2, Tony Evans 3 & Trish Chudleigh 4 1 Academic Division of Obstetrics and Gynaecology, Nottingham University
More informationLe dépistage prénatal First-trimester syndrome de Down. grossesse aneuploidies SUMMARY AGENCE D ÉVALUATION DES TECHNOLOGIES
Le dépistage prénatal du First-trimester syndrome de Down et prenatal d autres screening aneuploïdies au for premier Down trimestre syndrome de la and grossesse other aneuploidies SUMMARY AGENCE D ÉVALUATION
More informationfi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...
АВАВАКдлАмА дла длама АсАядлАмА АВА АсдлАя & MАядлдлАмАК TА. 4, T. 2, АВ. 113-118, 2005 fi АУ : Аяapplefi. fiapple АсА» Ас Ам, длappleapple Ас..., Ая: Аяapplefi. fiapple, АВАУ Ас, АсА» Ас Ам длappleapple
More informationThe First Trimester Screening program
The First Trimester Screening program The Fetal Medicine Foundation This guide has been designed to highlight the important clinical aspects of using the First Trimester Screening program. It is not intended
More informationNon-Invasive Prenatal Testing (NIPT) Factsheet
Introduction NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.
More informationFirst-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ
First-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ First-trimester prenatal screening for Down syndrome
More informationTrisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method
Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method Ghalia ASHOOR 1, Argyro SYNGELAKI 1, Eric WANG 2, Craig STRUBLE 2, Arnold OLIPHANT 2,
More informationCharts of fetal size: limb bones
BJOG: an International Journal of Obstetrics and Gynaecology August 2002, Vol. 109, pp. 919 929 Charts of fetal size: limb bones Lyn S. Chitty a, *, Douglas G. Altman b Objective To construct new size
More informationUltrasound evaluation of fetal gender at 12 14 weeks
Ultrasound evaluation of fetal gender at 12 14 weeks Marek Lubusky a,b, Martina Studnickova a, Ales Skrivanek a, Katherine Vomackova c, Martin Prochazka a Aims. The aim of this study was to assess the
More informationPrediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions
Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although
More informationFirst Trimester Screening for Down Syndrome
First Trimester Screening for Down Syndrome What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test
More informationFirst-trimester screening markers are altered in pregnancies conceived after IVF/ICSI
Ultrasound Obstet Gynecol 2009; 33: 8 17 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.6254 First-trimester screening markers are altered in pregnancies conceived
More informationQuality Assessment of Fetal Nuchal Translucency Measurements in the First Trimester of Pregnancy
en22 Original Article Quality Assessment of Fetal Nuchal Translucency Measurements in e First Trimester of Pregnancy Martin Hynek 1,2,4, David Stejskal 1, Jana Zvárová 3,4 1 Gennet, Center for Fetal Medicine,
More informationIncreased fetal nuchal translucency at 11 14 weeks
PRENATAL DIAGNOSIS Prenat Diagn 2002; 22: 308 315. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/ pd.308 Increased fetal nuchal translucency at 11 14 weeks Kypros H.
More informationThe first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands
FVV in ObGyn, 2014, 6 (1): 7-12 Preliminary report The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands P.J. Willems 1, H. Dierickx 1, ES. Vandenakker
More information11 13 +6 Weeks Scan Project Newsletter
USA FETAL MEDICINE FOUNDATION OF THE UNITED STATES OF A MERICA Non-profit Registration No.1635069 July 2007 11 13 +6 Weeks Scan Project Naomi Greene MPH RDMS RDCS 3940 Laurel Canyon Blvd. #838 Studio City,
More informationLEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns
More informationPrenatal Testing Special tests for your baby during pregnancy
English April 2006 [OTH-7750] There are a number of different prenatal (before birth) tests to check the development of your baby. Each test has advantages and disadvantages. This information is for people
More informationTrisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)
Trisomies 13 and 18 (Patau and Edward s syndrome) Trisomy 21 (Down syndrome) is the commonest chromosomal disorder at birth, and has been considered in detail in previous annual reports 23. Other relatively
More informationThe quadruple test screening for Down s syndrome and spina bifida
The quadruple test screening for Down s syndrome and spina bifida This leaflet provides information about a blood test to check for Down s syndrome and spina bifida. This test is available to you between
More informationEmbryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities
CME Article Embryonic Heart Rate as a Prognostic Factor for Chromosomal Abnormalities Deniz Oztekin, MD, Ozgur Oztekin, MD, Fatma I. Aydal, MD, Sivekar Tinar, MD, Zehra H. Adibelli, MD Objective. The purpose
More informationPrediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11 13 weeks
PRENATAL DIAGNOSIS Prenat Diagn 2011; 31: 66 74. Published online in Wiley Online Library (wileyonlinelibrary.com).2660 Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical
More informationyour questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal
More informationPrenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy This statement has been
More informationA. Evidence for an individually adjustable standard to assess birth weight:
Customised antenatal growth charts are designed to facilitate better supervision of fetal growth. The chart is printed out in early pregnancy, after confirmation of pregnancy dates, and allows serial plotting
More informationDown s Syndrome: Ultrasound Screening
October 2001 Down s Syndrome: Ultrasound Screening Hilary Hochberg Advanced Radiology Clerkship Dr. Gillian Lieberman Patient M.C. 32 year old female presents at 16 weeks gestational age with abnormal
More informationUltrasonography of the Fetal Thyroid
Article Ultrasonography of the Fetal Thyroid Nomograms Based on Biparietal Diameter and Gestational Age Angela C. Ranzini, MD, Cande V. Ananth, PhD, MPH, John C. Smulian, MD, MPH, Michelle Kung, Anita
More informationFirst-trimester Screening for Down Syndrome and. Other Aneuploidies: Methodological Issues. Peter van Heesch
First-trimester Screening for Down Syndrome and Other Aneuploidies: Methodological Issues Peter van Heesch First-trimester Screening for Down Syndrome and Other Aneuploidies: Methodological Issues Thesis,
More informationGenetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Testing and pregnancy GP s role 3 Counselling before and during pregnancy 3 Collecting the family history
More informationAssessment of Fetal Growth
Assessment of Fetal Growth Unit / Trust: 1. INTRODUCTION The aim of this guideline template is to outline the methods used to assess fetal growth and the referral pathways utilising customised antenatal
More informationWrongful deaths and rightful lives screening for Down syndrome
Wrongful deaths and rightful lives screening for Down syndrome Frank Buckley and Sue Buckley Prenatal screening for Down syndrome affects millions of pregnancies every year worldwide. The vast majority
More informationGutenberg Center in MALAGA
Introduction Gutenberg Center in MALAGA Gutenberg Center in Málaga opened in 1987 as a clinic to provide integral assisstance for women, divided into 6 Units, specialized in the different aspects of Obs
More informationPrenatal Screening Policies in Europe
Prenatal Screening Policies in Europe 2010 EUROCAT Central Registry Room 12L09, University of Ulster Newtownabbey, Co Antrim Northern Ireland, BT37 0QB Tel: +44 (0)28 90366639 Fax: +44 (0)28 90368341 Email:
More informationFetal echocardiography at 11 13 weeks by transabdominal high-frequency ultrasound
Ultrasound Obstet Gynecol 2011; 37: 296 301 Published online 10 February 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.8934 Fetal echocardiography at 11 13 weeks by transabdominal
More informationThis document covers the principles behind Gestation Adjusted Optimal Weight (GROW) for the following applications
This document covers the principles behind Gestation Adjusted Optimal Weight (GROW) for the following applications GROW-CC (customised centiles) - for calculating weight centiles individually or in a spreadsheet;
More informationNoninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationPosition Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013
Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013 Peter Benn (Chair), Antoni Borell, Rossa Chiu, Howard Cuckle,
More informationPrognosis of Very Large First-Trimester Hematomas
Case Series Prognosis of Very Large First-Trimester Hematomas Juliana Leite, MD, Pamela Ross, RDMS, RDCS, A. Cristina Rossi, MD, Philippe Jeanty, MD, PhD Objective. The aim of this study was to evaluate
More informationTHE USE OF FIRST TRIMESTER ULTRASOUND
SOGC CLINICAL PRACTICE GUIDELINES THE USE OF FIRST TRIMESTER ULTRASOUND This guideline has been reviewed by the Diagnostic Imaging Committee and approved by the Executive and Council of the Society of
More informationThe California Prenatal Screening Program
The California Prenatal Screening Program Quad Marker Screening One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester) Serum Integrated Screening Prenatal Patient Booklet - English
More informationCurrent Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma
No. 287, February 2013 Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma This committee opinion has been prepared by
More informationObstetrical Ultrasound and Prenatal Diagnostic Center
Obstetrical Ultrasound and Prenatal Diagnostic Center Prenatal Diagnosis: Options and Opportunities Learn about various screening options including Early Risk Assessment (ERA), now available to women of
More informationNoninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions
More informationTrisomy 13 (also called Patau s syndrome or T13)
Screening Programmes Fetal Anomaly Trisomy 13 (also called Patau s syndrome or T13) Information for parents Publication date: April 2012 Review date: April 2013 Version 2 117 Information sheet to help
More informationFetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis
Original Paper Received: August 22, 2013 Accepted after revision: September 17, 2013 Published online: December 7, 2013 Pregnancies Using Directed Cell-Free DNA Analysis Craig A. Struble a Argyro Syngelaki
More informationAim of maternal-foetal care
Prenatal screening of Down s syndrom in the first and the second trimester of pregnancy Drahomira Springer ULBLD and 1.LF UK Praha Aim of maternal-foetal care the uncomplicated birth of a healthy baby
More informationMeans, standard deviations and. and standard errors
CHAPTER 4 Means, standard deviations and standard errors 4.1 Introduction Change of units 4.2 Mean, median and mode Coefficient of variation 4.3 Measures of variation 4.4 Calculating the mean and standard
More informationTriploidy. rarechromo.org
Triploidy rarechromo.org Triploidy Triploidy is a disorder that arises at conception when a baby starts life in the womb with a complete extra set of chromosomes. Chromosomes are the microscopically small
More informationInclusion of Early Fetal Deaths in a Birth Defects Surveillance System
TERATOLOGY 64:S20 S25 (2001) Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System MATHIAS B. FORRESTER AND RUTH D. MERZ* Hawaii Birth Defects Program, Honolulu, Hawaii 96817 ABSTRACT
More informationLong-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester
Long-Term Prognosis of Pregnancies Complicated by Slow Embryonic Heart Rates in the Early First Trimester Peter M. Doubilet, MD, PhD, Carol B. Benson, MD, Jeanne S. Chow, MD Slow embryonic heart rates
More informationi_~~~~~~~~~~~~~~~~~~~~- A _L,"'...S.::.. E, pad - report of 92 cases with follow up of Antenatal diagnosis of cystic hygroma or nuchal survivors
F38 Archives ofdisease in Childhood 1996; 74: F38-F42 Antenatal diagnosis of cystic hygroma or nuchal pad - report of 92 cases with follow up of survivors P A Boyd, M Y Anthony, N Manning, C Lara Rodriguez,
More informationComplimentary and personal copy for
Complimentary and personal copy for www.thieme.com Publishing House and Copyright: 2015 by Georg Thieme Verlag KG Rüdigerstraße 14 70469 Stuttgart ISSN Any further use only by permission of the Publishing
More informationBirth Defects Monitoring in Japan -Possible Effects of Environmental Endocrine Disrupters-
Birth Defects Monitoring in Japan -Possible Effects of Environmental Endocrine Disrupters- Fumiki Hirahara Yokohama City University School of Medicine Thank you, Paul. It is my great pleasure to be here
More informationIntrauterine sonographic assessments of embryonic heart diameter
Human Reproduction vol.12 no.10 pp.2286 2291, 1997 Intrauterine sonographic assessments of embryonic heart diameter Toshiyuki Hata 1, Daisaku Senoh, Kohkichi Hata and Kohji Miyazaki Department of Obstetrics
More informationCONGENITAL HEART DISEASE
CONGENITAL HEART DISEASE Introduction Congenital heart disease (CHD) is the most common congenital disorder in newborns [1]. Due to definitional issues, there are large variations in prevalence estimates.
More informationNeural tube defects: open spina bifida (also called spina bifida cystica)
Screening Programmes Fetal Anomaly Neural tube defects: open spina bifida (also called spina bifida cystica) Information for health professionals Publication date: April 2012 Review date: April 2013 Version
More informationEffect of Increased Body Mass Index on the Accuracy of Estimated Fetal Weight by Sonography in Twins
Article Effect of Increased Body Mass Index on the Accuracy of Estimated Fetal Weight by Sonography in Twins Manisha Gandhi, MD, Lauren Ferrara, MD, Victoria Belogolovkin, MD, Erin Moshier, MS, Andrei
More informationIsolated Sonographic Markers for Detection of Fetal Down Syndrome in the Second Trimester of Pregnancy
Isolated Sonographic Markers for Detection of Fetal Down Syndrome in the Second Trimester of Pregnancy David A. Nyberg, MD, Vivienne L. Souter, MD, Amira El-Bastawissi, MBCB, PhD, Scott Young, MD, Fred
More informationFetal Lateral Ventricular Width: What Should Be Its Upper Limit?
Article Fetal Lateral Ventricular Width: What Should Be Its Upper Limit? A Prospective Cohort Study and Reanalysis of the Current and Previous Data Benny Almog, MD, Ronni Gamzu, MD, PhD, Reuven Achiron,
More informationF. I. VOS*, E. A. P. DE JONG-PLEIJ, L. S. M. RIBBERT, E. TROMP and C. M. BILARDO*
Ultrasound Obstet Gynecol 2012; 39: 636 641 Published online 10 April 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.10058 Three-dimensional ultrasound imaging and measurement
More informationReference intervals of gestational sac, yolk sac and embryo volumes using three-dimensional ultrasound
Ultrasound Obstet Gynecol 29; 34: 53 59 Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 1.12/uog.7348 Reference intervals of gestational sac, yolk sac and embryo volumes using
More informationChoices about first trimester ultrasound scans: A decision aid for pregnant women
Choices about first trimester ultrasound scans: A decision aid for pregnant women If you have any concerns about yourself or your baby/babies and want to talk to someone, please call: your family doctor
More informationBilling Guidelines for Obstetrical Services and PCO Responsibilities
Billing Guidelines for Obstetrical Services and PCO Responsibilities Providing obstetrical services to UnitedHealthcare Community Plan members and your patients is a collaborative effort. Complying with
More informationThe effect of maternal ABO blood groups and rhesus status on first trimester biochemical markers
The effect of maternal ABO blood groups and rhesus status on first trimester biochemical markers İlk trimester biyokimyasal belirteçleri üzerine maternal ABO ve Rh kan gruplarının etkisi Ahmet Cantuğ Çalışkan,
More informationExceptional People. Exceptional Care. Antenatal Appointment Schedule for Normal Healthy Women with Singleton Pregnancies
Exceptional People. Exceptional Care. Antenatal Appointment Schedule for Normal Healthy Women with Singleton Pregnancies First Antenatal Contact with the GP Obtain medical and obstetric history. Measure
More informationEvaluation and Follow-up of Fetal Hydronephrosis
Evaluation and Follow-up of Fetal Hydronephrosis Deborah M. Feldman, MD, Marvalyn DeCambre, MD, Erin Kong, Adam Borgida, MD, Mujgan Jamil, MBBS, Patrick McKenna, MD, James F. X. Egan, MD Objective. To
More informationUltrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester?
Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester? Laurence E. Shields, MD, Leslie A. Carpenter, MS, CGC, Karin M. Smith, RDMS, Hanh V. Nghiem, MD The objective of
More informationParvovirus B19 Infection in Pregnancy
Parvovirus B19 Infection in Pregnancy Information Pack Parvovirus B19 Infection in Pregnancy Information Booklet CONTENTS: THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT
More informationDifferentiation between normal and abnormal fetal growth
Differentiation between normal and abnormal fetal growth JASON GARDOSI MD FRCSE FRCOG Director, West Midlands Perinatal Institute, St Chad s Court, 213 Hagley Road, Birmingham B16 9RG, U.K. Tel +44 (0)121
More informationFirst trimester prenatal screening among women pregnant after IVF/ICSI
Human Reproduction Update Advance Access published April 20, 2012 Human Reproduction Update, Vol.0, No.0 pp. 1 10, 2012 doi:10.1093/humupd/dms010 First trimester prenatal screening among women pregnant
More informationSequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013
More informationAssessment and management of miscarriage
Assessment and management of miscarriage Dawn Miller is a Senior Lecturer in Women s Health at the Dunedin School of Medicine, University of Otago. She is also a doctor at Family Planning, Dunedin, and
More informationUmbilical and fetal middle cerebral artery Doppler at 35 37 weeks gestation in the prediction of adverse perinatal outcome
Ultrasound Obstet Gynecol 2015; 46: 82 92 Published online 1 June 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI: 1002/uog.14842 Umbilical and fetal middle cerebral artery Doppler at 35 37
More informationBirth prevalence The birth prevalence of Down s syndrome increases with maternal age from about 1 in 1500 under age 25 to about 1 in 100 at age 40
172 J Med Screen 1998;5:172 177 Review Natural history of Down s syndrome: a brief review for those involved in antenatal screening Joan Noble Department of Environmental and Preventive Medicine, Wolfson
More informationSupplementary online appendix
Supplementary online appendix 1 Table A1: Five-state sample: Data summary Year AZ CA MD NJ NY Total 1991 0 1,430 0 0 0 1,430 1992 0 1,428 0 0 0 1,428 1993 0 1,346 0 0 0 1,346 1994 0 1,410 0 0 0 1,410 1995
More information1) Write the following as an algebraic expression using x as the variable: Triple a number subtracted from the number
1) Write the following as an algebraic expression using x as the variable: Triple a number subtracted from the number A. 3(x - x) B. x 3 x C. 3x - x D. x - 3x 2) Write the following as an algebraic expression
More informationBirth defects. Report by the Secretariat
EXECUTIVE BOARD EB126/10 126th Session 3 December 2009 Provisional agenda item 4.7 Birth defects Report by the Secretariat 1. In May 2009 the Executive Board at its 125th session considered an agenda item
More informationUltrasound scans in pregnancy
Ultrasound scans in pregnancy www.antenatalscreening.wales.nhs.uk Copyright 2016 Public Health Wales NHS Trust. All rights reserved. Not to be reproduced in whole or in part without the permission of the
More informationA Guide to Prenatal Genetic Testing
Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests
More informationACTA FIRST TRIMESTER SCREENING AND DOWN SYNDROME UNIVERSITATIS OULUENSIS D 1107. Jaana Marttala OULU 2011 MEDICA
OULU 2011 D 1107 ACTA Jaana Marttala UNIVERSITATIS OULUENSIS D MEDICA FIRST TRIMESTER SCREENING AND DOWN SYNDROME UNIVERSITY OF OULU, FACULTY OF MEDICINE, INSTITUTE OF CLINICAL MEDICINE, DEPARTMENT OF
More information